Malignant Brain Neoplasm Clinical Trial
Official title:
Quantifying Tumor Respiration Using Oxygen-Enhanced Molecular MRI
This trial looks to study the safety and feasibility of using oxygen-enhanced molecular MRI to understand how cancer cells use oxygen differently than normal cells. Cancer cells tend to utilize (or not utilize) oxygen differently than normal cells. By using the oxygen-enhanced molecular MRI, researchers will be able to create spatial "maps" depicting areas of abnormal oxygen utilization unique to cancer. This type of information may be useful for diagnosing new cancers, understanding various "subtypes" of cancer that might utilize oxygen differently, or this information may be useful for evaluating new drugs that impact cancer metabolism.
PRIMARY OBJECTIVES: I. Determine the safety, feasibility, and sensitivity of oxygen-enhanced molecular magnetic resonance imaging (MRI) in healthy volunteers. II. Measure oxygen-enhanced molecular MRI characteristics in human brain tumors. OUTLINE: Participants undergo arterial spin labeling (ASL) MRI scan and amine chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging using amine proton CEST echo spin-and-gradient echo (SAGE) EPI (CEST-SAGE-EPI) while breathing normal room air (21% oxygen). Patients then undergo another ASL MRI and CEST-SAGE-EPI while breathing medical grade air (100% oxygen). Total ASL MRI and CEST-SAGE-EPI imaging scan time is 60 minutes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06377696 -
Remote Cognitive Assessment Battery and Wearable Device Monitoring Platform While Assessing the Impact of Metformin in Patients With History of Cranial Radiation Therapy
|
Phase 2 | |
| Recruiting |
NCT03510208 -
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
|
Phase 1/Phase 2 | |
| Completed |
NCT04067960 -
Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer
|
Early Phase 1 | |
| Completed |
NCT04456140 -
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
|
Phase 1 | |
| Recruiting |
NCT03649880 -
Feasibility of FMISO in Brain Tumors
|
Phase 2 | |
| Not yet recruiting |
NCT06132685 -
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
|
Phase 2 | |
| Withdrawn |
NCT04521946 -
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
|
Phase 1 | |
| Completed |
NCT04752267 -
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
|
Early Phase 1 | |
| Recruiting |
NCT04510051 -
CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
|
Phase 1 | |
| Recruiting |
NCT04475640 -
Cancer Genetic Testing in Ethnic Populations
|
N/A | |
| Recruiting |
NCT04459273 -
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT05139043 -
Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients With Primary or Metastatic Brain Tumors
|
Phase 2 |